We are live on ! Find out more
RKDA icon

Arcadia Biosciences
RKDA

14 hedge funds and large institutions have $3.53M invested in Arcadia Biosciences in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

17% more funds holding

Funds holding: 12 → 14 (+2)

0% less ownership

Funds ownership: 0.02% → 0.01% (-0%)

31% less capital invested

Capital invested by funds: $5.11M → $3.53M (-$1.58M)

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Holders
14
Holders Change
+2
Holders Change %
+16.67%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
1
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LRPA
L. Roy Papp & Associates
Arizona
+$44.5K
2
BlackRock
BlackRock
New York
+$34.5K
3
Creative Planning
Creative Planning
Kansas
+$27.3K
4
Renaissance Technologies
Renaissance Technologies
New York
+$27.3K
5
Citadel Advisors
Citadel Advisors
Florida
+$25.1K

Top Sellers

Rank Fund Capital Flow
1
WRF
Waddell & Reed Financial
Kansas
-$412K
2
VKH
Virtu KCG Holdings
New York
-$32.3K
3
Norges Bank
Norges Bank
Norway
-$13.7K
4
TRCT
Tower Research Capital (TRC)
New York
-$13.7K
5
Goldman Sachs
Goldman Sachs
New York
-$2.87K
Name Holding Trade Value Shares
Change 		Change in
Stake
WRF
1
Waddell & Reed Financial
Kansas
$3M -$412K -573 -9%
LRPA
2
L. Roy Papp & Associates
Arizona
$285K +$44.5K +62 +13%
BCM
3
Bridgeway Capital Management
Texas
$51K – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$46K – – –
BlackRock
5
BlackRock
New York
$27K +$34.5K +48 New
Norges Bank
6
Norges Bank
Norway
$21K -$13.7K -19 -33%
Renaissance Technologies
7
Renaissance Technologies
New York
$21K +$27.3K +38 New
Creative Planning
8
Creative Planning
Kansas
$20K +$27.3K +38 New
Citadel Advisors
9
Citadel Advisors
Florida
$19K +$25.1K +35 New
Geode Capital Management
10
Geode Capital Management
Massachusetts
$17K – – –
Northern Trust
11
Northern Trust
Illinois
$11K +$14.4K +20 New
Goldman Sachs
12
Goldman Sachs
New York
$9K -$2.87K -4 -20%
VKH
13
Virtu KCG Holdings
New York
$7K -$32.3K -45 -78%
TRCT
14
Tower Research Capital (TRC)
New York
$1K -$13.7K -19 -95%
FDCDDQ
15
Federation des caisses Desjardins du Quebec
Quebec, Canada
$7 – – –
Wells Fargo
16
Wells Fargo
California
– -$2K -3 Closed

RKDA Hedge Fund Activity: Q1 2017 in Review

14 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q1 2017, worth a combined $3.53M — down 31% from $5.11M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new RKDA positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 5 trimmed.

The largest buyer was L. Roy Papp & Associates, adding an estimated $44.5K. The largest seller was Waddell & Reed Financial, cutting an estimated $412K.

  • 14 institutional investors held Arcadia Biosciences (RKDA) as of Q1 2017, up from 12 in Q4 2016.
  • Funds reported $3.53M of Arcadia Biosciences stock for Q1 2017, down 31% quarter-over-quarter.
  • 5 funds opened new Arcadia Biosciences positions in Q1 2017 and 1 closed out, a net change of +4 holders.
  • The largest Arcadia Biosciences buyer in Q1 2017 was L. Roy Papp & Associates, an estimated $44.5K added.
  • The largest Arcadia Biosciences seller in Q1 2017 was Waddell & Reed Financial, an estimated $412K sold.

Based on aggregated 13F filings for Q1 2017.